Clinical Trials

Manhattan Hematology Oncology Associates

AML-FLT3

Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.

The study will evaluate treatments with:
ASP2215 (Gilteritinib)
ASP2215 Plus Azacitidine
Azacitidine Alone

Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
212-689-6791 x 5
mailto:info@mhony.com

AML- FLT3/IDT

Now enrolling patients for a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
212-689-6791 x 5
mailto:info@mhony.com

CLL

Now enrolling patients for the InformCLL Registry. The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens.

This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL).

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
212-689-6791 x 5
mailto:info@mhony.com

Mantle Cell Lymphoma

Now enrolling patients in a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in patients with Previously Untreated Mantle Cell Lymphoma.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
212-689-6791 x 5
mailto:info@mhony.com

Hodgkin Lymphoma

Now Enrolling a Phase II Study of Oral HDAC-inhibitor Abexinostat in Patients with Relapsed or Refractory Follicular Lymphoma

Inhibition of histone deacytelases (HDAC) has emerged as a promising therapeutic strategy in hematologic malignancies. Abexinostat is a novel, oral, broad-spectrum phenyl hydroxamic acid–based HDAC inhibitor.

This Phase II study is now enrolling patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat tablets in a "one week on, one week off" schedule.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Karen Haglof, M.D.

For additional information:
Please contact our Clinical Research Coordinators

212-689-6791 ext 228 Phenoia Browne
212-689-6791 ext 105 Peter Okpara
clinicaltrials@mhony.com

Leukemia and Lymphomas CLL/SLL and MCL

Now enrolling patients for a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies

You are being asked to take part in a research study because you have chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or mantle cell lymphoma (MCL). This research study is evaluating an investigational drug, called cirmtuzumab, in combination with a standard drug, called ibrutinib (Imbruvica®), as a possible treatment for patients with CLL/SLL or MCL.

MAKE AN APPOINTMENT

MHOA Principle Investigator
Alec Goldenberg, M.D.

For additional information:
Please contact our Clinical Research Coordinators

212-689-6791 ext 228 Phenoia Browne
212-689-6791 ext 105 Peter Okpara
clinicaltrials@mhony.com

Meet Our Doctors

Alec Goldenberg, M.D.

Dr. Goldenberg, Founding Physician of Manhattan Hematology Oncology Associates (MHOA), graduated Magna Cum Laude from Brandeis University with High Honors in Mathematics, before receiving his MD from The Johns Hopkins University School of Medicine in 1980. He completed his internship and residency at Bellevue-New York University Hospitals, where he was also Chief Resident. Dr. Goldenberg continued his training as a fellow at Memorial Sloan Kettering in New York City before becoming the Director of the Hematology Clinic at the NYU Medical Center. Board certified in Internal Medicine and Medical Oncology, Dr. Goldenberg is currently a Clinical Associate Professor of Medicine at the New York University School of Medicine, and an Attending Physician at New York University Medical Center.


READ MORE

dr-g-mhony

Karen Haglof, M.D.

Dr. Karen Haglof, Associate Physician at Manhattan Hematology Oncology Associates (MHOA), graduated Summa Cum Laude from City University of New York, Hunter College before receiving her MD with Magna Cum Laude distinction from State University of New York. Completing her internship and residency in Internal Medicine at the University of Florida in Gainesville, Florida, Dr. Haglof continued her post-graduate medical training as a Hematology/Oncology Fellow at New York University in New York City. Dr. Haglof continued her strong relationship with NYU and Bellevue Hospitals, where she is currently an Attending Physician and Clinical Instructor in Hematology and Oncology.


READ MORE

dr-h-mhony

To schedule an appointment
or to get more information about
Manhattan Hematology Oncology Associates:

 
Office | 212-689-6791 Address | 157 E 32nd Street, New York, NY 10016

Patient Reviews

  • Laura Zente
    I was terrified to have the bone marrow biopsy procedure, but thanks to the special needle that Dr. Goldenberg invented, and his incredibly experienced nurse Priscilla, it was less painful than going to the dentist!
    Laura Zente
  • Kara A
    You are not just a medical chart to Dr. Goldenberg; you are a real person with real concerns. And now, 18 months later, I am celebrating One Year Cancer Free!
    Kara A
    Stage IV Colon Cancer
  • Peri I.
    What I realized by having the good fortune to find Dr. Goldenberg, is that the scary things on the internet about having a bone marrow biopsy are not true.
    Peri I.
    Essential Thombocythemia
  • Veronica Miller
    My time with Dr. Goldenberg has made me realize how strong a person I am. I put my life in his talented care, and in order to survive I learned to overcome my fear and look for the positive. Now that I am healthy, I share with my own patients the encouragement that he gave to me to get up and walk, and to make movement one of the keys to reclaiming health.
    Veronica Miller
    Multiple Myeloma
  • Ed from Yonkers
    If not for Dr. Karen Haglof, I may not be doing so well right now. I am a very lucky person.
    Ed from Yonkers
    CLL
  • Dr. Marc Kantrowitz
    It is New York and there are plenty of good doctors. The trick is to find one who is an excellent doctor and a good person, and Dr. Goldenberg was that fit for me.
    Dr. Marc Kantrowitz
    Deep Vein Thrombosis (DVT)
  • Vincent Love
    I tend to be very cautious-in fact, I tend to see more of the “hole in the doughnut” while Dr. Haglof sees the whole thing. It’s comforting that she is optimistic and positive, and I like her a lot. I feel good again, and things are going in the right direction. So far so good..and I am in very competent hands!
    Vincent Love
    CLL
  • Laura Murray
    One of the best calls I made this year was to Dr. Goldenberg, on the one year anniversary of the date of my diagnosis. Out of the woods medically, thanks to an unrelated donor in Germany, I've now in a new role as a cancer patient advocate to increase awareness for the need of participation in the bone marrow registry. Thanks to Dr. Goldenberg's uniquely compassionate care, I am able to experience this past year as a gift in disguise.
    Laura Murray
    Hodgkin’s Lymphoma
  • Geoffrey Rogow
    Dr. Haglof is one of my favorite people on the planet and I would tell everyone about her. I am back to work and in remission. I can’t possibly repay her, but if I could find a way to repay Dr. Haglof, well..I’d never do anything else with my life!
    Geoffrey Rogow
    Primary mediastinal B-cell lymphoma
  • Sophia S.
    Dr. Goldenberg and his first-rate staff at Manhattan Hematology Oncology Associates have brilliantly and compassionately helped me navigate the trail to recovery.
    Sophia S.
    Acute Myeloid Leukemia
  • Shelley Blye
    I often think of how lucky I was to have chosen a physician that I was able to trust 100% as my advocate.
    Shelley Blye
    Liver Cancer
  • Irma Gotay
    The Cancer had me and Dr. Goldenberg to contend with. I never felt like a cancer patient, Dr. Goldenberg’s office felt like another home to me.
    Irma Gotay
    Stage III Breast Cancer
  • Barbara Lande
    My time with Dr. Goldenberg has made me realize how strong a person I am. I put my life in his talented care, and in order to survive I learned to overcome my fear and look for the positive. Now that I am healthy, I share with my own patients the encouragement that he gave to me to get up and walk, and to make movement one of the keys to reclaiming health. I would never go anywhere else!
    Barbara Lande
    Follicular Lymphoma
  • Eric H. Weinberger
    Dr. Haglof is a rare human being- funny, dedicated, and incredibly competent.
    Eric H. Weinberger
    Stage IV Lung Cancer
  • Victor Ledezma
    Dr. Haglof made the frightening process of surviving cancer easier by providing a sense of positivity throughout the course of my care.
    Victor Ledezma
    Stage 4 Hodgkin Lymphoma
  • Gregg Gordon & Caryn Gordon
    Dr. Goldenberg’s dedication extends to both his patients and to their families. When my husband Gregg was sick, Dr. Goldenberg took the time to encourage and endorse a book that our daughter Ali wrote to help other AML family members. Our family believes this kind of patient support from an oncologist is rare.
    Gregg Gordon & Caryn Gordon
    Acute Myeloid Leukemia
  • Carla Santini
    Dr. Goldenberg’s love for his work is unmatched and his medical expertise and overall core values related to patient management shine through every time.
    Carla Santini
    Breast Cancer